The Plasma Proteins Market in the United States 2025

 

The Plasma Proteins Market in the United States – 2025 provides historical sales in units and dollars of all the therapeutic plasma-derived proteins sold in the United States for the full 2025 year by company, as well the sales of recombinant factors and non-factor products. Plasma collections for all commercial and non-profit collectors are also profiled, along with historical data for comparisons. Early events in 2026 are also profiled. It has been published every year since 1974 in May/June, and has historical data for growth comparisons along with extensive historical commentary to place the current market in the proper context in this large and complex market. It also analyzes recent developments regarding plasma supply (US plasma collections totals including collection volumes by company) and fractionation, product distribution and new therapeutic plasma proteins. The companies fractionating plasma and selling products in the United States are profiled. It is the MRB’s flagship report insight gleamed from the market year after year. The full report is US $27,000 while individual sections are also available. 

The report is delivered electronically (Excel and pdf files). Contact us at info@marketingresearchbureau.com for more information or the full Table of Contents and list of tables and charts.

THE PLASMA PROTEINS MARKET IN THE UNITED STATES – 2025

TABLE OF CONTENTS

 

Page 

14

29

77

98

147

147

199

211

236

309

326

351

365

375

384

405

 

 

EXECUTIVE SUMMARY

 1) PLASMA COLLECTIONS

2) PLASMA FRACTIONATION

3) MARKET OVERVIEW

4) IMMUNE GLOBULIN MARKET

4.1) IVIG & SCIG MARKETS

4.2) HYPERIMMUNE GLOBULINS

5) ALBUMIN MARKET

6) HEMOPHILIA CARE MARKET (Hemo A, B, VWD, Rare Factors, etc.)

7) PROTHROMBIN COMPLEX (PCC) & FIBRINOGEN

8) ALPHA-1 ANTITRYPSIN MARKET (AAT)

9) C-1 ESTERASE INHIBITOR MARKET (C1-INH)

10) ANTITHROMBIN III AND PROTEIN C MARKETS

11) FIBRIN SEALANT AND BIOSURGERY MARKET

12) DISTRIBUTION OF PLASMA PRODUCTS

13) PROFILES OF THE MAJOR COMPANIES